Sanchez-Ramos L, Chen A H, Kaunitz A M, Gaudier F L, Delke I
Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville, USA.
Obstet Gynecol. 1997 Jun;89(6):909-12. doi: 10.1016/s0029-7844(97)00113-0.
To evaluate the safety and clinical effectiveness of intravaginal misoprostol, a synthetic prostaglandin E1 analogue, for labor induction in gravidas with premature rupture of membranes (PROM) at term.
One hundred forty-one pregnant women with term PROM were assigned randomly to one of two induction groups: 1) intravaginal misoprostol or 2) intravenous oxytocin by continuous infusion.
Seventy subjects were allocated to the misoprostol group and 71 to the oxytocin group. The mean (+/- standard deviation) interval from induction to delivery was significantly shorter in the misoprostol group (416 +/- 276 compared with 539 +/- 372 minutes; P = .04). In 85.7% of patients in the misoprostol group, only one dose was required. Intrapartum complication rates, mode of delivery, and neonatal or maternal adverse event rates were similar in the two treatment groups. Uterine tachysystole occurred more frequently with misoprostol than with oxytocin (28.6% compared with 14.0%; P < .04).
Intravaginal administration of misoprostol induces labor safely and effectively in patients with PROM at term.
评估合成前列腺素E1类似物米索前列醇经阴道给药用于足月胎膜早破孕妇引产的安全性和临床有效性。
141例足月胎膜早破孕妇被随机分为两个引产组之一：1）米索前列醇经阴道给药组；2）静脉持续输注缩宫素组。
70例受试者被分配到米索前列醇组，71例被分配到缩宫素组。米索前列醇组从引产到分娩的平均（±标准差）间隔时间显著缩短（416±276分钟，而缩宫素组为539±372分钟；P = 0.04）。米索前列醇组85.7%的患者仅需一剂药物。两个治疗组的产时并发症发生率、分娩方式以及新生儿或产妇不良事件发生率相似。米索前列醇组子宫收缩过速的发生率高于缩宫素组（28.6%对14.0%；P < 0.04）。
米索前列醇经阴道给药可安全有效地诱导足月胎膜早破患者分娩。
